Details for Patent: 6,221,383
✉ Email this page to a colleague
| Title: | Solubility parameter based drug delivery system and method for altering drug saturation concentration |
| Abstract: | A blend of at least two polymers, or at least one polymer and a soluble polyvinylpyrrolidone, in combination with a drug provides a pressure-sensitive adhesive composition for a transdermal drug delivery system in which the drug is delivered from the pressure-sensitive adhesive composition and through dermis when the pressure-sensitive adhesive composition is in contact with human skin. According to the invention, soluble polyvinylpyrrolidone can be used to prevent crystallization of the drug, without affecting the rate of drug delivery from the pressure-sensitive adhesive composition. |
| Inventor(s): | Miranda; Jesus (Miami, FL), Sablotsky; Steven (Miami, FL) |
| Assignee: | Noven Pharmaceuticals, Inc. (Miami, FL) |
| Filing Date: | May 25, 1999 |
| Application Number: | 09/318,121 |
| Claims: | 1. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of: (a) a rubber adhesive, wherein the rubber adhesive is present in an amount from 5% to 97% by weight of the total composition; (b) a polyacrylate in an amount from 1% to 85% by weight of the total composition, wherein the ratio of the polyacrylate to the rubber adhesive is from 2:98 to 96:4; (c) a therapeutically effective amount a mixture of two or more drugs for transdermal drug delivery, wherein the drug is present in an amount weight 0.1% to 50% by weight of the total composition, and wherein said two or more drugs include an androgenic steroid and an estrogen; and (d) a soluble polyvinylpyrrolidone, wherein the soluble polyvinylpyrrolidone is present in an amount of 1% to 20% by weight of the total composition, wherein the ratio of the drug to the soluble polyvinylpyrrolidone is from 1:10 to 10:1, and wherein the amount of soluble polyvinylpyrrolidone is sufficient to solubilize all of the drug which is present in an amount that would exceed its solubility in a composition that contains a rubber adhesive and a polyacrylate, but lacks soluble polyvinylpyrrolidone. 2. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of: (a) a synthetic elastomeric polymer; (b) a soluble polyvinylpyrrolidone; (c) a therapeutically effective amount of a drug or a mixture of two or more drugs for transdermal drug delivery, wherein said two or more drugs include an androgenic steroid and an estrogen; and (d) optionally one or more additives selected from the group consisting of enhancers, fillers, plasticizers, tackifying agents, and co-solvents. 3. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of (a) a rubber; (b) a soluble polyvinylpyrrolidone; (c) a therapeutically effective amount of a drug or a mixture of two or more drugs for transdermal drug delivery, wherein said two or more drugs include an androgenic steroid and an estrogen; and (d) optionally one or more additives selected from the group consisting of enhancers, fillers, plasticizers, tackifying agents, and co-solvents. 4. A pressure-sensitive adhesive composition suitable for use in a transdermal drug delivery system, which composition comprises a blend of: (a) a rubber adhesive, wherein the rubber adhesive is present in an amount from 5% to 97% by weight of the total composition; (b) a polyacrylate in an amount from 1% to 85% by weight of the total composition, wherein the ratio of the polyacrylate to the rubber adhesive is from 2:98 to 96:4; (c) a therapeutically effective amount a drug for transdermal drug delivery, wherein the drug is present in an amount of 0.1% to 50% by weight of the total composition, and wherein said drug is selected from the group consisting of terbinafine, sumatriptan, physostigmine, loratadine, simvastatin, pravstatin, methimazole, alendranate, etidronate, ropinirole, pramipexole, fenoldopam, and nimesulide; and (d) a soluble polyvinylpyrrolidone, wherein the soluble polyvinylpyrrolidone is present in an amount of 1% to 20% by weight of the total composition, wherein the ratio of the drug to the soluble polyvinylpyrrolidone is from 1:10 to 10:1, and wherein the amount of soluble polyvinylpyrrolidone is sufficient to solubilize all of the drug which is present in an amount that would exceed its solubility in a composition that contains a rubber adhesive and a polyacrylate, but lacks soluble polyvinylpyrrolidone. |
